BRUKINSA (zanubrutinib) Logo
BRUKINSA (zanubrutinib) Logo

BRUKINSA patients can call the myBeiGene® patient support program to talk to a dedicated nurse: 1-833-BEIGENE (1-833-234-4363)

The National Comprehensive Cancer Network® (NCCN®) recommends zanubrutinib (BRUKINSA®) as a preferred treatment option for people with CLL/SLL who have or haven’t been treated before and with or without certain genetic mutations, known as del(17p) or TP53 mutations*

NCCN is a not-for-profit alliance of 32 leading cancer centers in the United States devoted to patient care, research, and education. The organization creates cancer guidelines that are considered the standard to guide treatment decisions.

*Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma V.2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed January 25, 2023. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

How does BRUKINSA work?
BRUKINSA, also known as zanubrutinib, is a type of targeted treatment known as a BTK inhibitor because it works to shut down (or inhibit) a protein within cancerous B cells called Bruton’s tyrosine kinase (BTK). Shutting down the BTK protein is important because this protein sends non-stop signals to cancerous B cells, such as those that cause chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), to grow and spread.
What makes BRUKINSA different

Although some treatment options for CLL/SLL may seem similar, every treatment is different. Knowing the differences can help you take an active role in discussing treatment options with your doctor.

Blocks up to 100% of BTK

BRUKINSA was designed to block BTK signaling and keep it shut down around the clock. This may help stop the signaling in cancerous B cells.

  • BRUKINSA has been shown to block 100% of BTK in blood cells and 94% to 100% of BTK in lymph nodes when taken at the recommended total daily dose of 320 mg. The significance of blocking up to 100% of BTK on treatment responses has not been established
More effective than some other approved CLL/SLL treatments

In 2 clinical trials, BRUKINSA was shown to be much better than some other treatments approved for CLL/SLL. Two types of responses were studied: progression-free survival (PFS) and overall response rate (ORR).

  • Explore BRUKINSA efficacy for patients who have not been treated, and for previously treated patients
Effective for different kinds of patients

BRUKINSA was shown to be effective, regardless of patients’ age, genetic mutations, or other health conditions such as atrial fibrillation/flutter.

  • Responses were seen in patients treated with BRUKINSA, including those with genetic mutations, such as del(17p)
Low treatment discontinuation due to side effects

Fewer patients discontinued BRUKINSA due to side effects, 8% for previously untreated (compared to 14% with BR) and 15% for previously treated (compared to 22% with ibrutinib) patients.

Flexible dosing

BRUKINSA is an oral treatment that can be prescribed on a dosing schedule that meets your needs.

  • BRUKINSA can be taken either once daily (4 capsules) or twice daily (2 capsules in the morning and 2 capsules later in the day). Talk to your doctor about which dosing schedule is best for you
  • BRUKINSA can be taken at home, unlike many chemotherapy treatments, which have to be administered at a hospital or clinic
LEARN MORE ABOUT BRUKINSA EFFICACY AND SAFETY IN CLL/SLL

Meet Wendy, a CLL patient who has been on BRUKINSA for 2 years and 5 months

What is CLL/SLL?

CLL and SLL are cancers caused by abnormal B cells (also known as B lymphocytes). B cells are a type of white blood cell found in your blood and bone marrow. When B cells develop normally, they help protect the body from infection and disease.

In CLL, cancer cells are found mostly in the blood and bone marrow. In SLL, cancer cells are found mostly in the lymph nodes and spleen. The treatment for CLL and SLL is very similar because they are both caused by abnormal B cells.

For those taking BRUKINSA and their caregivers, is here to help

The myBeiGene patient support program provides a dedicated Oncology Nurse Advocate who is available to answer questions and provide information about your cancer, treatment with BRUKINSA, follow-up support, and more.

Call 1-833-BEIGENE (1-833-234-4363) Monday through Friday, 8 AM to 8 PM Eastern Time to speak with an Oncology Nurse Advocate today.

VISIT myBeiGene.com TO LEARN MORE

myBeiGene® is not insurance and does not guarantee product coverage or reimbursement.

IMPORTANT SAFETY INFORMATION

What should I tell my healthcare provider before taking BRUKINSA?

Before taking BRUKINSA, tell your healthcare provider about all of your medical conditions, including if you:

  • have bleeding problems.
  • have had recent surgery or plan to have surgery. Your healthcare provider may stop BRUKINSA for any planned medical, surgical, or dental procedure.
  • have an infection.
  • have or had heart rhythm problems.
  • have high blood pressure.
  • have liver problems, including a history of hepatitis B virus (HBV) infection.
  • are pregnant or plan to become pregnant. BRUKINSA can harm your unborn baby. If you are able to become pregnant, your healthcare provider may do a pregnancy test before starting treatment with BRUKINSA.
    • Females should avoid getting pregnant during treatment and for 1 week after the last dose of BRUKINSA. You should use effective birth control (contraception) during treatment and for 1 week after the last dose of BRUKINSA.
    • Males should avoid getting female partners pregnant during treatment and for 1 week after the last dose of BRUKINSA. You should use effective birth control (contraception) during treatment and for 1 week after the last dose of BRUKINSA.
  • are breastfeeding or plan to breastfeed. It is not known if BRUKINSA passes into your breast milk. Do not breastfeed during treatment with BRUKINSA and for 2 weeks after the last dose of BRUKINSA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking BRUKINSA with certain other medications may affect how BRUKINSA works and can cause side effects.

What are the possible side effects of BRUKINSA?

BRUKINSA may cause serious side effects, including:

  • Bleeding problems (hemorrhage). Bleeding problems are common with BRUKINSA, and can be serious and may lead to death. Your risk of bleeding may increase if you are also taking a blood thinner medicine. Tell your healthcare provider if you have any signs or symptoms of bleeding, including:
    • blood in your stools or black stools (looks like tar)
    • pink or brown urine
    • unexpected bleeding, or bleeding that is severe or you cannot control
    • vomit blood or vomit that looks like coffee grounds
    • cough up blood or blood clots
    • increased bruising
    • dizziness
    • weakness
    • confusion
    • change in speech
    • headache that lasts a long time
  • Infections that can be serious and may lead to death. Tell your healthcare provider right away if you have fever, chills, or flu-like symptoms.
  • Decrease in blood cell counts (white blood cells, platelets, and red blood cells). Your healthcare provider should do blood tests during treatment with BRUKINSA to check your blood counts.
  • Second primary cancers. New cancers have happened in people during treatment with BRUKINSA, including cancers of the skin or other organs. Your healthcare provider will check you for other cancers during treatment with BRUKINSA. Use sun protection when you are outside in sunlight.
  • Heart rhythm problems (atrial fibrillation, atrial flutter, and ventricular arrhythmias) that can be serious and may lead to death. Tell your healthcare provider if you have any of the following signs or symptoms:
    • your heartbeat is fast or irregular
    • feel lightheaded or dizzy
    • pass out (faint)
    • shortness of breath
    • chest discomfort

The most common side effects of BRUKINSA include:

  • decreased white blood cell count
  • upper respiratory tract infection
  • decreased platelet count
  • muscle, bone, or joint pain

These are not all the possible side effects of BRUKINSA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is BRUKINSA?

BRUKINSA is a prescription medicine used to treat adults with:

  • Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Waldenström’s macroglobulinemia (WM).
  • Mantle cell lymphoma (MCL) who have received at least one prior treatment for their cancer.
  • Marginal zone lymphoma (MZL) when the disease has come back or did not respond to treatment and who have received at least one certain type of treatment.

It is not known if BRUKINSA is safe and effective in children.

Please see full Prescribing Information including Patient Information.

Learn more about treatment with BRUKINSA

WMMCLMZL
The BRUKINSA Difference
BeiGene, Ltd. Opens in a new window.
Privacy Policy